Abstract. Chronic myelogenous leukemia (CML) is a neoplasm of myeloid progenitor cells expressing Bcr-Abl fusion protein.
Introduction
Chronic myelogenous leukemia (CML) is a neoplasm of myeloid progenitor cells expressing 210-kDa Bcr-Abl fusion protein. The inhibitor of Bcr-Abl kinase, imatinib, has a remarkable clinical response in chronic phase of the majority of patients (1, 2) . However, some patients with CML are less likely to respond to imatinib, and then develop imatinib resistance (3) . Recent studies showed that signaling pathways, especially the mammalian target of rapamycin (mTOR) pathway, can increase responses to imatinib and overcome its resistance (4) . Studies reported that mTOR and its downstream effectors could be activated in cell lines expressing Bcr-Abl in a Bcr-Abl kinase-dependent manner (5) (6) (7) .
mTOR is a serine/threonine kinase that plays an important role within the PI3K/AKT/mTOR signaling pathway (8) . The two major substrates of mTOR are ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), which regulates cap-dependent transcription and translation of a great number of proteins by phosphorylation. Studies have indicated that the molecules of mTOR pathway were concerned with tumorigenesis and mTOR inhibitors (rapamycin and RAD001) could affect sensitivity of tumors (including leukemias) to various forms of therapy (9) (10) (11) (12) (13) . The result of the recent studies also indicated that the signaling pathway of mTOR became an important therapeutic target for leukemias (14, 15) . However, understanding of the role of mTOR pathway in tumorigenesis and the impact of rapamycin in clinic treatment of myelogenous leukemia is unclear, and more studies need to be done.
Therefore, we examined expression of mTOR and its downstream molecules (p70S6K and 4E-BP1) in bone marrow cells from patients with chronic myelogenous leukemia. In addition, we investigated cell growth, apoptosis and expression of mTOR pathway molecules in cell line of K562 after rapamycin treatment.
Materials and methods
Patients. Thirty-four cases of CML treated at the Second Hospital, Hebei Medical University were included in this study from June 2009 to December 2010. Among them, there were 23 cases of male and 11 cases of female, and the median age (range) of 34 cases were 54 years (33-65). Ten healthy donors were collected as control group. After informed consent was obtained from all subjects, mononuclear cells were collected by bone marrow aspiration. (20, 40 and 80 nmol/l) were washed with ice-cold PBS. Total protein was extracted using a lysis buffer containing 1% Triton X-100, 150 mmol/l NaCl, 2 mmol/l EDTA, 1 mmol/l sodium fluoride, 1 mmol/l sodium orthovanadate, 1 mmol/l phenylmethylsulfonyl fluoride, 2 mg/ ml aprotinin and 0.5 mmol/l DTT. After lysates were cleared by centrifugation (12,000 rpm) for 30 min, protein concentration was measured using a standard Coomassie brilliant blue (CBB) total protein assay kit (Jiancheng Bioengineering, Nanjing, China).
Western blot analysis. Protein samples were run on a 7.5%-15% SDS-PAGE gel and transferred to PVDF membrane. After blocking non-specific binding sites with 5% non-fat milk in TBS-T (20 mmol/l Tris-HCl, pH 7.4, 150 mmol/l NaCl, 0.1% Tween-20) for 60 min, the membranes were incubated overnight at 4 ℃ with primary antibody (mTOR, p-mTOR, 4E-BP1, p-4E-BP1, p70S6K and p-p70S6K; Cell Singaling, USA. bcl-2 and caspase-3, Santa Cruz, CA). Then the membranes were probed with HRP-conjugated secondary antibody (at 1:5,000 dilution) for 60 min at 37˚C. After being washed 3 times with TTBS, the membranes were developed by ECL chemiluminescent detection system. (20, 40 and 80 nmol/l) were harvested. Total RNA was extracted using TRIzol Reagent (Invitrogen, USA) according to the manufacturer's instructions. After cDNA being obtained by reverse transcription (Promega, USA), PCR was performed with gene-specific primers. The fragment of GAPDH cDNA gene was used as an internal control (Table Ⅰ) .
Reverse transcription PCR (RT-PCR) analysis. K562 cells treated with rapamycin
The 25 µl PCR reaction mixes contained 5 µl of 5X Reaction Buffer (Promega, USA), 0.35 µl of 10 mmol/l dNTP, 2.5 pm forward and reverse primers, 0.15 µl GoTaq DNA Polymerase (Promega, USA) and 1.5 µl cDNA. The reaction was initiated at 94˚C for 5 min, and then performed using the following amplification cycles: denaturation at 94˚C for 50 sec, annealing at 55˚C for 30 sec, and extension at 72˚C for 30 sec. The number of amplification cycles was estimated by a preliminary study to optimize the exponential phase of PCR. The final cycle at 72˚C for 10 min was also included. PCR products were visualized by gel electrophoresis on 1.5% agarose (w/v) gel, and then viewed using the ultraviolet photometry (UVP) bioimaging system.
Statistical analysis.
Values are presented as means ± standard deviation (SD). Statistical differences were performed with one-way analysis of variance (ANOVA) by the statistical software of SPSS 13.0 for Windows (SPSS, Chicago, IL). The clinical variables were analyzed by the χ 2 test and Fisher's exact test. P<0.05 was considered statistically significant.
Results

Expression of mTOR signaling molecules in bone marrow cells with CML.
The phosphorylation status of mTOR, 4E-BP1 and p70S6K was detected in 34 patients with CML.
We also determined the expression of total 4E-BP1 and p70S6K in these cases. p-mTOR was examined in 24 of 34 (70.6%), higher than that in normal bone marrow cells. Moreover, the phosphory lation of 4E-BP1 and p70S6K was more detected in CML patients (Table Ⅱ, Fig. 1 ). Moreover, p-4E-BP1 was determined in 26 of 27 cases with positive expression of total 4E-BP1 (96.3%), significantly higher than in normal bone marrow (4/8, 50%, P<0.05). In 29 cases of CML with expression of total p70S6K, 25 (86.2%) cases showed phosphorylation, and only 2 (28.6%) cases showed p-p70S6K expression in 7 cases of normal bone marrow with total p70S6K expression (P<0.05). We found that mTOR signaling is frequently activated in CML.
Rapamycin decreased phosphorylation of mTOR and downstream molecules in K562 cells. The effect of rapamycin on mTOR and its downstream molecules by Western blot and RT-PCR was shown in Fig. 2 . The expression of mTOR displayed no significant variation between groups of K562 cells with rapamycin and solvent treatment (P>0.05). Nevertheless, the phosphorylation of mTOR was significantly decreased in groups with rapamycin treatment than that in solvent group (P<0.05, Fig. 2A) . Thus, these data indicate that rapamycin inhibits phosphorylation of mTOR.
To further explore the mechanism of mTOR and its substrates, we examined the expression of 4E-BP1 and p70S6K. The significantly lower expression of 4E-BP1 and p70S6K Table II . Expression of mTOR signaling proteins in chronic myelogenous leukemia. at mRNA level were seen in K562 cells after rapamycin treatment (P<0.05, Fig. 2B ). Moreover, Western blot data also showed coincident results with RT-PCR, especially the phosphorylations of 4E-BP1 and p70S6K were significantly decreased in groups of cells with rapamycin treatment than that in solvent group (P<0.05, Fig. 2A ). The findings confirmed that rapamycin inhibited phosphorylation of mTOR, and then had an effect on its substrates in K562 cells.
Group Normal bone marrow (10) Chronic myelogenous leukemia (34) --------------------------------------------------------------------------------------------------------------------------------------------------
Rapamycin inhibited growth of K562 cells.
Effect of rapamycin on K562 cells was measured by MTT assay after treatment. The cell viability in groups with rapamycin treatment displayed a significant decrease in a dose-dependent manner ranging from 5 to 1000 nmol/l (P<0.05, Fig. 3 ). rapamycin, as compared with the control group. Furthermore, the significant increase of G 0 /G 1 phase cells and decrease of S phase cells were found in groups with rapamycin treatment for 48 h, as well as the treated groups for 24 h. The results indicated that rapamycin could induce K562 cells to arrest in G 1 phase.
Rapamycin arrests K562 cells at G
We also assessed expression of several cell cycle regulators at mRNA level after rapamycin treatment (Fig. 5) . The expression of cyclinD1 mRNA was significantly decreased (P<0.05). On the contrary, higher expression of p21 at mRNA level was detected in cells with rapamycin treatment (P<0.05). Expression of cyclinB1 show no variety in K562 cells after rapamycin incubation.
Rapamycin induces apoptosis in K562 cells.
To determine if rapamycin resulted in increased apoptosis of K562 cells, we studied apoptosis after treatment of rapamycin with increasing concentrations for 24 h. As shown in Fig. 6A (Q1, damaged cells; Q2, late apoptotic cells; Q3, living cells; and Q4, early apoptotic cells), the percentage of apoptotic cells in treated groups with 20, 40 and 80 nmol/l was 15.6, 20.7 and 24.1%, respectively, significantly higher than in control group (7.9%, P<0.05). The result indicated that treatment with 20 nmol/l or higher concentrations of rapamycin increased apoptotic cells, including early and late apoptotic cells, in a concentrationdependent manner.
To study the underlying apoptotic mechanisms, expression of apoptosis regulators, caspase-3 and bcl-2, were assessed after treatment with 20, 40 and 80 nmol/l rapamycin (Fig. 6B) . There was decreased expression of bcl-2 after rapamycin treatment. Meanwhile, the caspase-3 activity (17 kD) was only detected in K562 cells in treated groups (Fig. 6B) . Our findings confirmed that rapamycin induced apoptosis in K562 cells.
Discussion
PI3K/AKT/mTOR signaling pathway plays important roles in many cancers including various hematopoietic neoplasms. PI-3 kinase, induced by Bcr-Abl through a direct association with its regulatory subunit, could activate mTOR upon phosphorylation by Akt in cell line of CML (5) . In addition, rapamycin, as the inhibitor of mTOR, was shown to combine with PI3K/PDK1 inhibitor (BAG956) in a non-antagonistic fashion against Bcr-Abl expressing cells (16) . To understand the signaling pathway of mTOR, we measured expression of mTOR and its down-stream molecules in bone marrow cells with CML. Our results showed significantly higher expression of p-mTOR in bone marrow cells from patients, and phosphorylation of 4E-BP1 and p70S6K was also detected at high level in CML cases. It suggested that the mTOR pathway was activated in CML.
Previous data showed that PI3K/AKT/mTOR was a central regulatory pathway of protein translation involved in the regulation of cell proliferation, differentiation and survival (17, 18) . mTOR activation (p-mTOR) could phosphorylate its downstream targets. Phosphorylated p70S6K had an effect on cell growth through inducing protein synthesis and cell survival (19) . Moreover, activated p70S6K could increase the translation of 5'-terminal oligopyrimidine tract mRNAs (20) . 4E-BP1 phosphorylation (Ser37; Thr46; Ser65; Thr70) leads to releasing the eukaryotic initiation factor 4E (eIF4E). eIF4E plays key roles in translation of 5' capped mRNAs, including transcripts encoding growth promoting molecules. Our study showed that 4E-BP1 and p70S6K were phosphorylated at high level in patients with CML. Of note, treatment of CML cell line with rapamycin also resulted in a decrease of phosphorylation of 4E-BP1 and p70S6K. Consequently, rapamycin, the mTOR inhibitor, could decrease the phosphorylation of mTOR, and then downstream molecules of mTOR were also decreased because of a lower level of p-mTOR.
Some studies reported that mTOR inhibitor had impact on many molecules related with cell growth, cell cycle and angiogenesis, such as p21, cyclin D1, cyclin-dependent kinase 2, p27 and VEGF (21) (22) (23) (24) . The data presented here showed that rapamycin could induce cell cycle arrest and apoptosis interfering with proliferation and survival pathways in K562 cells. The cell viability in groups with rapamycin treatment displayed a significant decrease in a dose-dependent manner. We also presented increase of G 0 /G 1 phase cells and decrease of S phase cells after rapamycin treatment. These findings indicated that rapamycin, as the inhibitor of mTOR, blocked cell cycle progression from G 1 to S phase via the inhibition of p70S6K and 4E-BP1, as reported previously (25, 26) . Recent study also showed that rapamycin and the silencing of mTOR expression using siRNA resulted in increased apoptosis (26) . Our study showed that treatment with 20 nmol/l or more rapamycin increased apoptotic cells, decreased expression of bcl-2 and activated caspase-3. The finding confirmed that rapamycin induced apoptosis in K562 cells.
In conclusion, the mTOR pathway might be involved in chronic myelogenous leukemia. Inhibition of the mTOR pathway interfers with cell proliferation and increase cell apoptosis in K562 cells. Our funding suggested that mTOR might be an important therapeutic target for myelogenous leukemia, especially patients with Bcr-Abl mutants who do not respond well to imatinib. Therefore, understanding of mTOR pathway should contribute to more efficient treatment for leukemia in the future.
